Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Pioglitazone in Combination with Moderate Dose Statin on Atherosclerotic Inflammation: Randomized Controlled Clinical Trial Using Serial FDG-PET/CT

  • Choo, Eun Ho (Department of Cardiology, The Catholic University of Korea College of Medicine) ;
  • Han, Eun-Ji (Department of Radiology, The Catholic University of Korea College of Medicine) ;
  • Kim, Chan Joon (Department of Cardiology, The Catholic University of Korea College of Medicine) ;
  • Kim, Sung-Hoon (Department of Radiology, The Catholic University of Korea College of Medicine) ;
  • O, Joo-Hyun (Department of Radiology, The Catholic University of Korea College of Medicine) ;
  • Chang, Kiyuk (Department of Radiology, The Catholic University of Korea College of Medicine) ;
  • Seung, Ki-Bae (Department of Cardiology, The Catholic University of Korea College of Medicine)
  • Received : 2017.09.16
  • Accepted : 2018.03.14
  • Published : 2018.07.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Non-statin therapy plus lower intensity statin might be an alternative in patients with coronary artery disease (CAD). A recent data suggested an anti-inflammatory therapy can reduce recurrent cardiovascular events and pioglitazone is also an intriguing inflammatory-modulating agent. However, limited data exist on whether pioglitazone on top of statins further attenuates plaque inflammation. Methods: Statin-$na\ddot{i}ve$ patients with stable CAD and carotid plaques of ${\geq}3mm$ were randomly prescribed moderate dose atorvastatin (20 mg/day), or moderate dose atorvastatin plus pioglitazone (30 mg/day) for 3 months. The primary endpoint was the change in the arterial inflammation of the carotid artery measured by $^{18}F$-fluorodeoxyglucose positron emission tomography/computed tomography ($^{18}F$-FDG-PET/CT) during 3 months. Results: Of the 41 randomized patients, 33 underwent an evaluation by fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT; 17 atorvastatin plus pioglitazone and 16 atorvastatin patients). The addition of pioglitazone significantly improved the insulin sensitivity and increased the high-density lipoprotein cholesterol after 3 months. Although a reduction in the (FDG) uptake by pioglitazone on top of atorvastatin in carotid arteries with plaque showed marginally statistical significance in the entire patient group (atorvastatin plus pioglitazone; $-0.10{\pm}0.07$ and atorvastatin $-0.06{\pm}0.04$, p=0.058), pioglitazone showed a further reduction of the fluorodeoxyglucose (FDG) uptake among patients who had a baseline FDG uptake above the median (atorvastatin plus pioglitazone; $-0.14{\pm}0.04$ and atorvastatin $-0.03{\pm}0.03$, p<0.001). Conclusions: Pioglitazone demonstrated marginally significant anti-inflammatory effects in addition to moderate dose atorvastatin. This may have been due to the lack of power of the study. However, pioglitazone may have an anti-inflammatory effect in those patients with high plaque inflammation (Trial registry at ClinicalTrials.gov, NCT01341730).

Keywords

Acknowledgement

Supported by : Ministry of Health, Welfare & Family Affairs

References

  1. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. https://doi.org/10.1056/NEJMoa050461
  2. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45. https://doi.org/10.1001/jama.294.19.2437
  3. Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation 2014;129:1303-9. https://doi.org/10.1161/CIRCULATIONAHA.113.003589
  4. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64. https://doi.org/10.1001/jama.2011.860
  5. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016;68:92-125. https://doi.org/10.1016/j.jacc.2016.03.519
  6. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31. https://doi.org/10.1056/NEJMoa1707914
  7. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89. https://doi.org/10.1016/S0140-6736(05)67528-9
  8. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8. https://doi.org/10.1001/jama.298.10.1180
  9. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-31. https://doi.org/10.1056/NEJMoa1506930
  10. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81. https://doi.org/10.1001/jama.296.21.joc60158
  11. Saremi A, Schwenke DC, Buchanan TA, et al. Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013;33:393-9. https://doi.org/10.1161/ATVBAHA.112.300346
  12. Mizoguchi M, Tahara N, Tahara A, et al. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging 2011;4:1110-8. https://doi.org/10.1016/j.jcmg.2011.08.007
  13. Forst T, Wilhelm B, Pfutzner A, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res 2008;5:298-303. https://doi.org/10.3132/dvdr.2008.043
  14. Hanefeld M, Marx N, Pfutzner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 2007;49:290-7. https://doi.org/10.1016/j.jacc.2006.08.054
  15. Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59. https://doi.org/10.1016/S0140-6736(11)61383-4
  16. Hwang BH, Kim MH, Chang K. Molecular imaging of high-risk atherosclerotic plaques: is it clinically translatable? Korean Circ J 2011;41:497-502. https://doi.org/10.4070/kcj.2011.41.9.497
  17. Tawakol A, Fayad ZA, Mogg R, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013;62:909-17. https://doi.org/10.1016/j.jacc.2013.04.066
  18. Pucci A, Formato L, Muscio M, et al. PPARgamma in coronary atherosclerosis: in vivo expression pattern and correlations with hyperlipidemic status and statin treatment. Atherosclerosis 2011;218:479-85. https://doi.org/10.1016/j.atherosclerosis.2011.06.009
  19. Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation 2007;116:2182-90. https://doi.org/10.1161/CIRCULATIONAHA.107.698852
  20. Cocker MS, Mc Ardle B, Spence JD, et al. Imaging atherosclerosis with hybrid [18F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. J Nucl Cardiol 2012;19:1211-25. https://doi.org/10.1007/s12350-012-9631-9
  21. Rudd JH, Myers KS, Bansilal S, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging 2009;2:107-15. https://doi.org/10.1161/CIRCIMAGING.108.811752
  22. van der Valk FM, Verweij SL, Zwinderman KA, et al. Thresholds for arterial wall inflammation quantified by 18F-FDG PET imaging: implications for vascular interventional studies. JACC Cardiovasc Imaging 2016;9:1198-207. https://doi.org/10.1016/j.jcmg.2016.04.007
  23. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2016;37:2999-3058. https://doi.org/10.1093/eurheartj/ehw272
  24. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014;35:1782-91. https://doi.org/10.1093/eurheartj/ehu203
  25. Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80. https://doi.org/10.1016/j.jacc.2006.12.048
  26. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31. https://doi.org/10.1172/JCI10370
  27. Chang K, Francis SA, Aikawa E, et al. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol 2010;30:1933-9. https://doi.org/10.1161/ATVBAHA.110.206342
  28. Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining potent statin therapy with other drugs to optimize simultaneous cardiovascular and metabolic benefits while minimizing adverse events. Korean Circ J 2017;47:432-9. https://doi.org/10.4070/kcj.2016.0406

Cited by

  1. Imaging Atherosclerosis by PET, With Emphasis on the Role of FDG and NaF as Potential Biomarkers for This Disorder vol.11, pp.None, 2020, https://doi.org/10.3389/fphys.2020.511391
  2. Atherosclerosis imaging using PET: Insights and applications vol.178, pp.11, 2018, https://doi.org/10.1111/bph.14868
  3. Advances in Radiopharmaceutical Sciences for Vascular Inflammation Imaging: Focus on Clinical Applications vol.26, pp.23, 2021, https://doi.org/10.3390/molecules26237111